ReviewInfection & chemotherapy2019
Treatment of Extrapulmonary Nontuberculous Mycobacterial Diseases.
Review in Infection & chemotherapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 71 citations in OpenAlex.
- Integrated Management of Mycobacterium abscessus Infections Following Aesthetic Fat Grafting: A Promising Combination of Targeted Medication and Minimally Invasive Surgery.Aesthetic plastic surgery · 2026Article
- Detection of Nontuberculous Mycobacterial Skin Infection by Next-Generation Sequencing: A Pilot Study.Journal of clinical medicine · 2026Article
- Article
- Diffuse large B-cell lymphoma mimicking musculoskeletal nontuberculous mycobacterial infection: A fatal diagnostic challenge.IDCases · 2026Article
- Review of the Canadian Nontuberculous Mycobacterial Disease Landscape-Challenges and Opportunities.Tropical medicine and infectious disease · 2025Review
- PaediatricOxford medical case reports · 2025Article
- The growing impact of nontuberculous mycobacteria: A multidisciplinary review of ecology, pathogenesis, diagnosis, and treatment.Infectious medicine · 2025Review
- Native Knee Septic Arthritis WithArthroplasty today · 2025Review
- Extrapulmonary Nontuberculous Mycobacteria Infection: The New-Age Neglected Infectious Disease.Cureus · 2025Review
- Language and racial disparities in treatment initiation for patients with pulmonary non-tuberculous mycobacteria.BMC research notes · 2025Article
- Case Report:Frontiers in immunology · 2025Article
- Diagnosis of nontuberculous mycobacterial infections using genomics and artificial intelligence-machine learning approaches: scope, progress and challenges.Frontiers in microbiology · 2025Review
- Extrapulmonary Comparisons BetweenInfection and drug resistance · 2025Review
- Chronic intractable nontuberculous mycobacterial-infected wound after acupuncture therapy in the elbow joint: A case report.World journal of clinical cases · 2024Article
- Nontuberculous Mycobacterial Infective Endocarditis: A Systematic Review of Clinical Characteristics and Outcomes.Open forum infectious diseases · 2024Article
- Nontuberculous mycobacterial myositis in dermatomyositis with long-term use of immunosuppressant: a case report.Skeletal radiology · 2024Article
- The Drug Susceptibility of Non-Tuberculous Mycobacteria (NTM) in a Referral Hospital in Rome from 2018 to 2023.Microorganisms · 2024Article
- Article
- Clinical Characteristics and Outcomes of Extrapulmonary Nontuberculous Mycobacterial Infections in a Tertiary-Care Hospital: A Retrospective Study.Journal of clinical medicine · 2024Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nontuberculous mycobacteria (NTM) diseases mainly manifest as pulmonary illnesses, but 20 -30% of NTM isolates originate from extrapulmonary diseases. These diseases cause a variety of clinical syndromes, including skin and soft-tissue infections, musculoskeletal infections, lymphadenitis, and disseminated disease. In skin and soft-tissue infections, musculoskeletal infections, prolonged treatment with combinations of antibiotics is effective in the treatment of NTM diseases, with surgery as an important complementary tool. The recommended duration of therapy for skin and soft-tissue infection is usually 2 - 4 months for mild disease and 6 months for severe disease, while treatment of musculoskeletal NTM disease usually requires at least 6 - 12 months. Management options of NTM lymphadenitis include surgical intervention, medical therapy, or observation. Treatment of disseminated NTM disease generally requires 6 to 12 months after immune restoration. However, despite a considerable increase in knowledge about NTM diseases, determining optimal treatment approaches remains a complex and challenging task.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.